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Abstract
Background:  Controversy exists around the preferred management of patients with brain
metastases and limited survival expectation, e.g. because of extensive brain involvement. Few
studies have focused on this particular group of patients.
Findings: A group of 24 patients with a large number of brain metastases, defined as 10 or more
on computed tomography scans, who were managed with palliative whole-brain radiotherapy
(WBRT), typically 30 Gy in 10 fractions, were analyzed. The median number of lesions was 14. The
patient characteristics were comparable to those of studies in the general population with brain
metastases, except for the fact that all patients had active sites of extracranial disease. Clinical
benefit, imaging response and overall survival were lower than expected. Median survival, for
example was 2 months. Trends towards better survival were found in patients with brain
metastases detected at first cancer diagnosis (synchronous manifestation, treatment naïve) and
those with better prognostic features according to the graded prognostic assessment (GPA) score.
Conclusions: The benefit of WBRT did not meet the expectations, suggesting that consideration
should be given to best supportive care including corticosteroid administration, especially if a
patient belongs to the lowest GPA class.
Findings
In patients with brain metastases, median overall survival
typically is limited to 4-6 months after administration of
palliative whole-brain radiotherapy (WBRT) [1]. It has
long been recognised that patients with limited brain
involvement, especially those with only one metastasis,
represent a relatively favorable subgroup and that many of
these patients are candidates for aggressive local treatment
with surgery or radiosurgery, which aims at durable local
control [2-10]. If the aim of local control can be achieved,
long-term survival might be possible. The outcome of
patients with extensive brain involvement is less well doc-
umented. Therefore, the purpose of the present study was
to analyse the presentation and outcome in patients with
a large number of brain metastases.
Since the opening of the Radiation Oncology facilities at
the authors' institution early in 2007, all patients with
brain metastases from solid tumors were entered into a
database. All patients with 10 or more brain metastases on
contrast-enhanced computed tomography (CT) scans and
without clinical and radiological signs of carcinomatous
meningitis were identified and retrospectively evaluated.
Treatment consisted of WBRT (10 fractions of 3 Gy or 5
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fractions of 4 Gy, individual steroid treatment as needed
for symptom control, median dose 16 mg dexamethasone
per day) without surgical resection or radiosurgery. We
used the Kaplan-Meier method to generate actuarial sur-
vival curves. These were compared with the log rank test.
Survival was calculated from the first day of treatment. All
patients had died at the time of analysis. A p-value < 0.05
was considered statistically significant.
The study group included 24 patients with 10 or more
brain metastases on CT scans (median 14, maximum
approximately 50). Two patients failed to complete their
prescribed treatment (continuous clinical deterioration),
but are included in this analysis. All patients had known
sites of extracranial disease, either uncontrolled primary
tumor or metastases. Table 1 shows the patient character-
istics. The maximum diameter of the largest brain lesion
was more than 3 cm in 4 patients, 2-3 cm in 8 patients, 1-
2 cm in 9 patients and less than 1 cm in 3 patients (17%,
33%, 37.5% and 12.5%, respectively).
The clinical benefit was assessed by the treating physician
in 21 patients (improvement of symptoms and/or per-
formance status). No information was available for 3
patients who immediately returned to their local hospi-
tals. Six patients (25%) were judged to have experienced
clinical improvement. Five had continuous deterioration
(21%), the other 10 were stable (42%). Follow-up CT was
scheduled approximately 5-6 weeks and 3 months after
WBRT. However, 7 patients were never assessed with
repeated CT imaging. In the remainder 17, 8 (33%) had
partial responses (decrease of all lesions by at least 50%
without appearance of new lesions) on at least one CT
examination. No complete remission was seen. Five of the
8 radiological responders also had clinical improvement.
In 6 patients with small cell lung cancer, two clinical and
one imaging response were seen. Median overall survival
was 2 months. At 6 months, 3 out of 24 patients (12.5%)
were alive. The maximum survival was 14 months. For the
recursive partitioning analysis (RPA) class II (Karnofsky
performance status (KPS) at least 70%, but at least one
adverse diagnostic feature such as age ≥65 years, uncon-
trolled primary tumor or extracranial metastases) [11],
median overall survival was 2.0 months and maximum
survival 14 months (in a patient with small cell lung can-
cer). For RPA class III, defined by KPS < 70, median overall
survival was 1.5 months and maximum survival 6 months
(in a patient with breast cancer). Figure 1 shows overall
survival according to the new graded prognostic assess-
ment (GPA) score [12], which performed better than the
Table 1: Patient characteristics
Median age, range 56 yrs., 36-80
Median KPS, range 70, 30-90
Metachronous vs. synchronous brain metastases 67 vs. 33% (16 vs. 8)
Without extracranial metastases 21% (5)
RPA class I vs. II vs. III 0:50:50% (0:12:12)
GPA class I vs. II vs. III vs. IV 0:0:37.5:62.5% (0:0:15:9)
Male vs. female gender 62.5 vs. 37.5% (15 vs. 9)
Non-small cell lung cancer 25% (6)
Small-cell lung cancer 25% (6)
Breast cancer 21% (5)
Malignant melanoma 17% (4)
Prostate cancer 4% (1)
Rectal cancer 4% (1)
Uterine cancer 4% (1)
KPS: Karnofsky performance status, RPA: recursive partitioning analysis [11], GPA: graded prognostic assessment [12]BMC Research Notes 2009, 2:247 http://www.biomedcentral.com/1756-0500/2/247
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RPA classes even if no significant p-value was calculated
with the available number of patients. The 4 GPA classes
are based on a score where 0, 0.5 or 1 point is assigned for
age, number of brain metastases, absence of extracranial
metastases and KPS. We were unable to identify any factor
significantly associated with better survival or likelihood
of clinical benefit. A trend was seen for better survival in
patients with synchronous manifestation of brain metas-
tases and those with better GPA score (p > 0.1).
This is to the authors' best knowledge the second report
that specifically addresses the outcome of patients with a
large number of multiple brain metastases, arbitrarily
defined as 10 or more on CT scans. One has to assume
that magnetic resonance imaging (MRI) would detect an
even higher number of lesions in these patients (possibly
some cases with leptomeningeal metastases too), but
there was no reason to perform MRI as this would not
have altered the patients' management. The cohort we
identified is relatively small and this fact should be taken
into account when interpreting the results, e.g., with
regard to power of statistical tests.
Despite possible limitations of small retrospective studies,
it is intriguing to see that all patients had active extracra-
nial disease (metastases and/or uncontrolled primary
tumor), thus none of them could be grouped into RPA
class I. Apart from this, patient characteristics were unre-
markable compared to other series. Overall survival in
RPA class III was at the lower end of the range of previ-
ously reported results [13-15]. However, class II had lower
median survival than the often quoted 3.5-4 months
[11,13-16]. This might result from the unusually
advanced brain involvement, which apparently is associ-
ated with lower than expected rates of clinical and imag-
ing response after typical palliative WBRT regimens. Also
for the complete group of patients, median overall sur-
vival (2 months) was poorer than expected. The GPA score
appears to predict the survival of our patients quite well,
yet no data are available for the favorable GPA classes.
Our survival data raise the question of whether these
patients can be managed with best supportive care includ-
ing steroids and anticonvulsants rather than WBRT plus
these measures. Head to head comparisons of the two
Kaplan-Meier estimates of overall survival in 24 patients with at least 10 brain metastases grouped by graded prognostic assess- ment (GPA) score, p > 0.1 Figure 1
Kaplan-Meier estimates of overall survival in 24 patients with at least 10 brain metastases grouped by graded 
prognostic assessment (GPA) score, p > 0.1. In the GPA system, the most unfavorable group has 0-1 points, the two 
intermediate groups have 1.5-2.5 and 3 points, respectively. The most favorable group has 3.5-4 points. None of the present 
patients had more than 2.5 points.
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strategies are not available, but a large series that included
118 patients managed with steroids without WBRT [17]
arrived at survival figures at 2 and 3 months which are
overlapping with ours. Some patients in the study actually
survived for 6 months and more [17]. No data on neuro-
logic function, performance status or quality of life is yet
available, although such endpoints might be more impor-
tant than slight differences in survival. The currently active
randomised Medical Research Council QUARTZ trial
comparing optimal supportive care and steroids with or
without WBRT in patients with non-small cell lung cancer
will contribute important information on the manage-
ment of patients with brain metastases and poor progno-
sis [18]. Omission of WBRT might be considered
especially in patients with active extracranial disease
where no further systemic treatment options exist and
where the extracranial tumor load is as threatening as the
brain involvement.
If WBRT seems indicated, different dose-/fractionation
regimens can be chosen. In patients with more than 3
brain metastases, the outcome was similar with WBRT
with 5 fractions of 4 Gy and 10 fractions of 3 Gy in the
series by Rades et al. [19]. The present results also indicate
that short course radiotherapy is preferable. For the occa-
sional patient with stable or responding extracranial dis-
ease, local control of the brain metastases might
eventually impact on survival. Several groups even offered
radiosurgery to patients with a large number of lesions
because the long-term local control probability after
WBRT alone is known to be inferior to that of radiosurgery
[1]. The study by Bhatnagar et al. suggests that patients
with 7-18 brain metastases might survive for a median of
6 months after upfront or salvage radiosurgery, but no
data for the subgroup with 10 or more metastases are
available [20]. One should also be aware of the fact that
radiosurgery-treated patients are different from those
reported here, e.g. with regard to imaging with MRI with
high doses of Gd-contrast media, smaller brain lesions
and often less aggressive extracranial disease. Own data
suggest that WBRT will control most of the small lesions
for the remaining life time [21,22] and therefore one
might prefer to administer radiosurgery boost to a limited
number of targets and select these according to size and
location, taking into account whether or not a lesion is
likely to contribute to neurological deficits and what the
risk of radiation toxicity will be. Amendola et al. decided
to administer radiosurgery without WBRT in 72 patients
with 10 or more lesions, but on average used 2 treatment
sessions (to the authors' knowledge the first paper specif-
ically addressing patients with 10 or more metastases)
[23]. Their patients had lesions detected by MRI with tri-
ple-dose Gd-contrast enhancement. The exact size distri-
bution was not reported. Nevertheless one has to assume
that brain involvement in our own patient group was
more extensive as it was depicted on CT scans. In both
series, all patients had extracranial disease. Median age
was comparable. Whether the radiosurgery study included
patients with small cell lung cancer was not reported.
Median survival after radiosurgery was 4.3 months and 6-
months survival approximately 37% (estimated from the
published graphs), i.e. better than in our series but infe-
rior to typical radiosurgery series in patients with few
brain metastases. The contribution of selection bias to
these results is difficult to estimate. In conclusion, the typ-
ical patient with estimated survival of approximately 2
months has two options: best supportive care or addi-
tional short course WBRT. Prospective data on neurologic
function, symptom load and quality of life need to be col-
lected to support decision making in a situation where
aggressive oncological treatment no longer is appropriate.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CN, AP and AD participated in the design of the study, CN
and AP collected patient data and follow-up information,
CN carried out the statistical analysis, CN, AP and AD
drafted the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
None. Sources of funding: none.
References
1. Khuntia D, Brown P, Li J, Mehta MP: Whole-brain radiotherapy in
the management of brain metastasis.  J Clin Oncol 2006,
24:1295-1304.
2. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio
RJ, Markesberry WR, Macdonald JS, Young B: A randomized trial
of surgery in the treatment of single metastases of the brain.
N Engl J Med 1990, 322:494-500.
3. Smalley SR, Laws ER Jr, O'Fallon JR, Shaw EG, Schray MF: Resection
for solitary brain metastasis. Role of adjuvant radiation and
prognostic variables in 229 patients.  J Neurosurg 1992,
77:531-540.
4. Noordijk EM, Vecht CJ, Haaxma-Reiche J, Padberg GW, Voormolen
JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorf AR:
The choice of treatment of single brain metastasis should be
based on extracranial tumor activity and age.  Int J Radiat Oncol
Biol Phys 1994, 29:711-71.
5. Auchter RM, Lamond JP, Alexander E III, Buatti JM, Chappell R, Fried-
man WA, Kinsella TJ, Levin AB, Noyes WR, Schultz CJ, Loeffler JS,
Mehta MP: A multiinstitutional outcome and prognostic fac-
tor analysis of radiosurgery for resectable single brain
metastasis.  Int J Radiat Oncol Biol Phys 1996, 35:27-35.
6. Andrews C, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell
MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rot-
man M, Mehta MP, Curran WJ Jr: Whole brain radiation therapy
with or without stereotactic radiosurgery boost for patients
with one to three brain metastases: phase III results of the
RTOG 9508 randomised trial.  Lancet 2004, 363:1665-1672.
7. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K,
Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hay-
akawa K, Katoh N, Kobashi G: Stereotactic radiosurgery plus
whole-brain radiation therapy vs. stereotactic radiosurgery
alone for treatment of brain metastases.  JAMA 2006,
295:2483-2491.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Research Notes 2009, 2:247 http://www.biomedcentral.com/1756-0500/2/247
Page 5 of 5
(page number not for citation purposes)
8. Kondziolka D, Martin JJ, Flickinger JC, Friedland DM, Brufsky AM,
Baar J, Agarwala S, Kirkwood JM, Lunsford LD: Long-term survi-
vors after gamma knife radiosurgery for brain metastases.
Cancer 2005, 104:2784-2791.
9. Rades D, Bohlen G, Pluemer A, Veninga T, Hanssens P, Dunst J, Schild
SE:  Stereotactic radiosurgery alone versus resection plus
whole-brain radiotherapy for 1 or 2 brain metastases in
recursive partitioning analysis class 1 and 2 patients.  Cancer
2007, 109:2515-2521.
10. Nieder C, Astner ST, Grosu AL, Andratschke NH, Molls M: The role
of postoperative radiotherapy after resection of a single
brain metastasis: combined analysis of 643 patients.  Strahlen-
ther Onkol 2007, 183:576-580.
11. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T,
McKenna WG, Byhardt R: Recursive partitioning analysis (RPA)
of prognostic factors in three Radiation Therapy Oncology
Group (RTOG) brain metastases trials.  Int J Radiat Oncol Biol
Phys 1997, 37:745-751.
12. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W: A new
prognostic index and comparison to three other indices for
patients with brain metastases: an analysis of 1,960 patients
in the RTOG database.  Int J Radiat Oncol Biol Phys 2008,
70:510-514.
13. Lutterbach J, Bartelt S, Stancu E, Guttenberger R: Patients with
brain metastases: hope for recursive partitioning analysis
(RPA) class 3.  Radiother Oncol 2000, 63:339-345.
14. Nieder C, Nestle U, Motaref B, Walter K, Niewald M, Schnabel K:
Prognostic factors in brain metastases: should patients be
selected for aggressive treatment according to recursive
partitioning analysis (RPA) classes?  Int J Radiat Oncol Biol Phys
2000, 46:297-302.
15. Saito EY, Viani GA, Ferrigno R, Nakamura RA, Novaes PE, Pellizzon
CA, Fogaroli RC, Conte MA, Salvajoli JV: Whole brain radiation
therapy in management of brain metastasis: results and
prognostic factors.  Radiat Oncol 2006, 1:20.
16. Gaspar LE, Scott C, Murray K, Curran W: Validation of the RTOG
recursive partitioning analysis (RPA) classification for brain
metastases.  Int J Radiat Oncol Biol Phys 2000, 47:1001-1006.
17. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens
PE, Schmitz PI: Identification of prognostic factors in patients
with brain metastases: a review of 1292 patients.  Int J Radiat
Oncol Biol Phys 1999, 43:795-803.
18. Khanduri S, Gerrard G, Barton R, Mulvenna P, Lee SM: Clinical trials
assessing the optimal management of brain metastases - the
state of play.  Clin Oncol (R Coll Radiol) 2006, 18:744-746.
19. Rades D, Kieckebusch S, Lohynska R, Veninga T, Stalpers LJ, Dunst J,
Schild SE: Reduction of overall treatment time in patients
irradiated for more than three brain metastases.  Int J Radiat
Oncol Biol Phys 2007, 69:1509-1513.
20. Bhatnagar AK, Kondziolka D, Lunsford LD, Flickinger JC: Recursive
partitioning analysis of prognostic factors for patients with
four or more intracranial metastases treated with radiosur-
gery.  Technol Cancer Res Treat 2007, 6:153-160.
21. Nieder C, Berberich W, Nestle U, Niewald M, Walter K, Schnabel K:
Relation between local result and total dose of radiotherapy
for brain metastases.  Int J Radiat Oncol Biol Phys 1995, 33:349-355.
22. Nieder C, Nestle U, Walter K, Niewald M, Schnabel K: Dose/effect
relationships for brain metastases.  J Cancer Res Clin Oncol 1998,
124:346-350.
23. Amendola BE, Wolf A, Coy SR, Amendola MA: Radiosurgery as
palliation for brain metastases: a retrospective review of 72
patients harboring multiple lesions at presentation.  J Neuro-
surg 2002, 97(Suppl 5):511-514.